Arrowhead Pharmaceuticals · 2 hours ago
Scientist/Senior Scientist, Antibody Engineering
Arrowhead Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative drugs for genetic diseases. The successful candidate will play a key role in antibody engineering to support platform development and drug delivery initiatives, requiring extensive hands-on experience in phage display and antibody characterization.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Design and construct mutant phage libraries for antibody affinity maturation or humanization
Perform molecular cloning, mutagenesis, antibody gene assembly, and expression vector design
Express and purify recombinant antibodies using bacterial and mammalian expression systems
Perform binding, specific and in vitro functional assays
Collaborate with cross-functional project teams to advance lead antibodies through drug development stages
Maintain accurate documentation and present findings at internal meetings
Qualification
Required
Ph.D. in Biology, Biochemistry, Molecular Biology, or a related field
Hands-on experience with phage display technology for antibody engineering
Proficiency in molecular cloning, PCR, and mutagenesis
Experience with antibody expression and purification using E. coli, HEK293, and CHO systems
Strong analytical and problem-solving skills, with the ability to troubleshoot experiments independently
Excellent record-keeping, communication, and collaboration skills
Proven ability to adapt to fast pace and evolving research priorities
Track record of scientific productivity, including peer-reviewed publications, conference presentations, or patents
Additional experience in molecular biology and/or antibody discovery is highly desirable
Preferred
Industry or postdoc experience
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$1.62BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2024-11-26Post Ipo Equity· $325M
2024-08-08Post Ipo Debt· $400M
2024-01-03Post Ipo Equity· $450M
Leadership Team
Recent News
2025-12-27
Los Angeles Business Journal
2025-12-24
Morningstar.com
2025-12-16
Company data provided by crunchbase